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Abstract 
Recurrent or “de novo” AA amyloidosis in the renal allograft is rarely described. We describe a case 
of severe nephrotic syndrome in a recipient of a kidney graft with previous diagnosis of polycystic 
nephropathy whose etiological disease was diagnosed as AA amyloidosis possibly TNF receptor-
associated periodic syndrome (TRAPS) related only after the renal transplantation. TRAPS is a rare 
hereditary inflammatory disease never reported as a de novo diagnosis in the transplantation setting, to 
the best of our knowledge. Biopsy of the renal graft, indicated for the recent onset of heavy 
proteinuria, and genetic investigation were the clue for diagnosis.  
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Introduction 
AA amyloidosis is a disorder characterized by extracellular deposition of amyloid A protein, derived 
from the precursor serum amyloid A (SAA), in the form of fibrils, which leads to a progressive organ 
dysfunction. SAA is an acute-phase protein produced by hepatocytes in response to inflammation. 
Kidney transplant is an accepted treatment for patients with renal involvement and end-stage kidney 
disease. Recurrent AA amyloidosis is infrequent and graft loss caused by this condition is uncommon 
(1). The first occurrence of “de novo” secondary amyloidosis in a kidney transplant recipient was 
described in 1993 (2). Since then, few other cases have been reported; an underlying chronic 
inflammatory disease was recognised in most of these cases. We report the case of a patients suffering 
from polycystic kidney disease in whom a diagnosis of AA amyloidosis was performed “de novo” in 
the renal allograft, with rapid failure of graft function. Lacking any evidence for underlying 
inflammatory disease, a genetic screening was performed. Only when subsequent investigations 
showed one of the low penetrance mutations related with the TNF Receptor-Associated Periodic 
Syndrome (TRAPS), a quite rare hereditary inflammatory disorder, could the association be suspected. 
Colchicine therapy, recognized as an effective drug for treatment and prevention of familial 
Mediterranean fever (FMF) related amyloidosis, was successfully used in our patient to treat 
symptoms and complications of the inflammatory syndrome. 
Case report 
We report the case of a 50-year-old caucasian man from Southern Italy, affected with polycystic 
kidney disease, who developed a picture consistent with secondary amyloidosis in a kidney allograft. 
The diagnosis of polycystic kidney disease was made in 1999. No other significant comorbidity was 
reported. Hemodialysis was initiated in 2007 and in December 2009 he underwent an uneventful 
kidney transplantation from a deceased donor in another Italian transplantation center. He was 
discharged on triple immunosuppressive therapy (cyclosporine, mycophenolate mofetil and steroids) 
with a good renal function (sCr 1.1 mg/dl, proteinuria 0.1 g/day). In the following months one episode 
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of Cytomegalic infection and some episodes of urinary tract infections were successfully treated. In 
June 2011, because of an episode of abdominal pain of unknown cause, associated with mild myalgia 
and arthralgia, the patient was hospitalized in our center. His renal function was worsened (sCr 4.9 
mg/dl) and a nephrotic range proteinuria was detected (8 g/day). No serum and urinary monoclonal 
components were found, immunological tests (rheumatoid factor, antinuclear, double strand anti-DNA 
and anti-neutrophil cytoplasmatic antibodies, cryoglobulins, IgG, IgA, IgM and C4 levels) were 
negative apart from hypocomplementemia C3. When clinical and nephrological conditions were 
improved by means of albumin infusions and diuretic therapy, the patient underwent a renal biopsy. 
The sample submitted contained 17 glomeruli. All glomeruli showed mesangial periodic acid-Schiff-
positive amorphous material, also present in the vessels, in the tubuli and focally in the interstitium. 
This material stained Congo red positive and demonstrated apple-green birefringence under polarized 
light. Immunofluorescence microscopy was negative for K and λ light chains and positive for P and A 
components. The diagnosis was in favour of AA amyloidosis. Laboratory and instrumental 
investigations were performed in order to exclude chronic inflammatory diseases and infections even 
in the absence of suggestive clinical signs (during the hospitalization the patient became completely 
asymptomatic for inflammation), including a total body PET, the Quantiferon test, the screening for 
Inflammatory Bowel Diseases and Celiac Disease. All tests were negative. Serum amyloid A (SAA) 
test ranged between 40-60 mg/l (normal values < 6.4 mg/l). Investigation of the MEFV gene, encoding 
for marenostrin, was found negative for the most common mutations in the mediterranean area 
(mutations analyzed: E148Q, P369S, F479L, M680I (G/C), M680I (G/A), I692del, M694V, M694I, 
K695R, V726A, A744S, R761H; detection rate 85%). So we decided to perform investigations for 
other genetic autoinflammatory syndromes (table 1). Meanwhile, the right native kidney was removed 
to rule out any infection or malignancies (on the basis of flank pain and CT imaging) and the intestinal 
mucosa was biopsied because of a severe hemorrhagic colitis (which was histologically demonstrated 
as CMV related). In both specimens AA amyloidosis was demonstrated. sCr initially decreased up to 
2.5 mg/dl but subsequently worsened again and proteinuria reached the value of 20 g/day. 
Antiproteinuric therapy (ACE inhibitors) and also the increase of cyclosporine dosage with the aim of 
procuring a nephrotoxic effect both failed in obtaining an improvement of proteinuria. Hemodialysis 
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was started in December 2011. The immunosuppressive therapy was reduced and the graft was not 
removed. In the same month a repeated echocardiography demonstrated the onset of cardiac 
involvement (thickening and increased echogenicity of the interventricular septum), which was absent 
in a previously performed test. A part from the need to resume the dialytic treatment for the worsening 
renal function and uremic symptoms, a therapy focused on suppressing or reducing the inflammatory 
status was considered, particularly in view of the cardiac involvement. Eprosidate, recently proposed 
as a modality of interrupting amyloid fibril deposition (3) but not yet available in our country, could 
not be obtained, not even for compassionate use in our patient, in view of the severe renal impairment. 
So we decided to use colchicine at the dose of 0.5 mg/day to treat the inflammation syndrome. When 
we started with the drug, hemodialysis had already been initiated. The drug was well  tolerated and 
after nine months of therapy the patient is doing well, has a good quality of life without any new sign 
of AA amyloidosis related systemic complications. His SAA is persistently within the normal range 
(1.4 mg/l at the last determination). Two months after the replacement of dialysis we obtained the 
results of the genetic tests that detected the low penetrance mutation R92Q on TNFRSF1A gene, 
considered a risk factor for TNF receptor-associated periodic syndrome (TRAPS) (4-6). So we opted 
for a case of AA amyloidosis in a renal allograft recipient TRAPS associated, to the best of our 
knowledge. The patient's follow-up is now being performed by a reference center for the disease, 
where further studies on MEVF gene will be performed. 
Discussion 
The most frequent complication of AA Amyloidosis is renal disease characterized by nephrotic 
syndrome and a progressive decline of renal function. Kidney transplant can be performed in 
hemodialysis patients with renal involvement although the importance of a careful screening and 
management of both cardiovascular and infectious complications to reduce the high risk of mortality 
have been recently stressed (7). Recurrent AA amyloidosis in the renal allograft has been documented 
in patients with ankylosing spondylitis, rheumatoid arthritis, Familial Mediterranean Fever (FMF), 
Crohn disease, chronic pyelonephritis and tubercolosis (8). De novo AA amyloidosis has rarely been 
reported. We can assume that we were describing a case of AA amyloidosis with acutely developed 
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signs and symptoms, because of the physiological values of proteinuria before dialysis and in the early 
post transplantation course and because of the rate of progression of the amyloidotic disease. The 
clinical course in our patient was particularly aggressive with a rapid decline in renal function and the 
progressive appearance of signs of systemic involvement in spite of minimal clinical symptoms of a 
chronic inflammatory syndrome. Only the biopsy of the renal graft allowed the identification of an 
unexpected disorder leading us to a more appropriate etiological and diagnostic process. On the basis 
of the second line genetic investigation, AA amyloidosis was presumed to be related to TRAPS, a rare 
hereditary inflammatory disease never reported as a de novo diagnosis in the transplantation setting, to 
the best of our knowledge. TRAPS is caused by autosomal-dominant mutations in TNFRSF1A, the 
gene that encodes for the tumor necrosis factor receptor superfamily 1 A, the main cell surface 
receptor for TNF. The mutations of this gene result in an upregulation of the inflammatory responses. 
Onset is usually in childhood; clinical manifestations include fever, migratory erythematous macular 
rashes, periorbital edema, myalgia, arthralgia and abdominal pain of relapsing and remitting nature 
(4). “A posteriori”, either the myalgia or the arthralgia and the abdominal pain could be interpreted as 
TRAPS related symptoms. Also some previous episodes of transitory cutaneous rashes of unexplained 
nature were reported by the patient at an in-depth and targeted questioning. Amyloidosis is reported in 
15% of cases of TRAPS (5). Our patient shows that this complication may be the first manifestation of 
TRAPS, even in the absence of clear clinical symptoms of inflammation. The delayed diagnosis of the 
rare genetic disorder is not uncommon. The case can be considered unusual since only after the onset 
of the heavy proteinuria, due to the occurrence of AA amyloidosis in the graft, the affection could be 
thoroughly investigated and the demonstration of the other sites of AA fibril deposition could be 
sought. Morever, the association between AA amyloidosis and TRAPS was acquired only thanks to 
the “second line” genetic investigation and not on the basis of a clinical suspicion. The TRAPS related 
symptoms were very mild, no recurrent fever attack was reported by the patient in his medical history. 
When histological and immunohistochemical analysis demostrate an AA amyloidosis, and particularly 
in absence of significant infective/inflammatory disease, a thorough genetic investigation should be 
performed. Although colchicine therapy is validated only for the treatment of FMF, in our patient, so 
far, it has proved to be effective in controlling the chronic inflammatory state. Although the response 
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to colchicine and AA amyloidosis are two sufficient criteria for the clinical diagnosis of FMF (table 2) 
(9), we believe that our patient’s symptoms, the late onset of the disease and the genetic alteration are 
more indicative of a TRAPS. A total of 114 sequence variants of the TNFRSF 1A have been recorded 
so far, of which 75 are associated with a TRAPS phenotype (10). The status of R92Q sequence has not 
been fully determined, but appears rather as an incomplete penetrance mutation suggesting that 
additional pathogenetic mechanism could be involved. We wonder if the mild infections, that the 
patient developed only after the kidney transplantation, could have acted as exogenous environmental 
factors triggering the TRAPS symptoms in a condition of a genetic predisposition. We are aware that 
in the last few years three different drugs have been tested and used for treatment of TRAPS related 
sumptoms: etanercept, anakinra and most recently canakinumab (11-13). None of these drugs was 
considered for our patient during the hospitalization in our unit because the evidence in favour of the 
genetic disease was obtained afterwards. In conclusion, we report a case of severe nephrotic syndrome 
in a transplanted patient with previous diagnosis of polycystic kidney disease whose etiological 
disease was diagnosed as AA amyloidosis possibly TRAPS associated. The renal biopsy and a genetic 
investigation were the clue for diagnosis, of outmost importance also in view of the option of 
retransplantation, although this has not yet been required by the patient. Thanks to colchicine therapy, 
we have obtained, so far, good results in controlling the underlying inflammatory state, so improving 
also the patient's quality of life, opening the possibility of a retransplant option.  
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Table 1: PERIODIC FEVERS 
DISEASE 
GENE 
CHROMOSOME 
PROTEIN TRANSMISSION CLINICAL FEATURES 
Familial 
mediterranean 
fever (FMF) 
MEVF 
16p13.3 
Pyryn 
Autosomal 
recessive 
Short duration of fever episodes 
(1-2 days). Serositis and arthritis. 
Erysipelas-like erythema. High 
incidence of renal amyloidosis in 
untreated patients. 
TNF receptor 
associated 
periodic 
syndrome 
TNFRSF1A 
12p13 
P55 THF 
receptor 
Autosomal 
dominant 
Prolonged fever episodes (1-3 
weeks). Abdominal pain. Skin 
rashes. Myalgias and arthritis. 
Orbital oedema. Incidence of 
renal amyloidosis: 15%. 
Mevalonate 
kinase 
deficiency 
MVK      
12q24 
Mevalonate 
kinase 
Autosomal 
recessive 
Duration of fever episodes: 4-5 
days. Abdominal pain, vomiting 
and diarrhoea. Splenomegaly. 
Amyloidosis is rare. 
NALP12-
associated 
periodic Fever 
NALP12 
19q13 
NALP12 
Autosomal 
dominant 
Periodic fever after cold exposure. 
Hearing loss. 
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Table 2: Tel-Hashomer diagnostic criteria for Familial Mediterranean Fever (FMF) 
MAJOR CRITERIA MINOR CRITERIA 
Recurrent fever episodes and serositis Recurrent fever episodes 
Evidence of AA amyloidosis Erysipelas-like erythema 
Good response to colchicine Family history for FMF (1° grade) 
Diagnosis with 2 major criteria or 1 major criteria + 2 minor criteria.  
Possible diagnosis with 1 major criteria and 1 minor criteria 
 
